After-Hours Stock Movers 09/28: (AEGR) (PIR) (GSAT) Higher; (ITCI) (ATNM) (PRGS) Lower (more...)
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Today's After-Hours Movers
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) 66.2% LOWER; announced top-line results from the second Phase 3 clinical trial (Study 302) of ITI-007, an oral, first-in-class investigational medicine for the treatment of schizophrenia. In this trial, neither dose of ITI-007 separated from placebo on the primary endpoint, change from baseline on the Positive and Negative Syndrome Scale (PANSS) total score, in the pre-defined patient population. The active control, risperidone, did separate from placebo. In this trial, ITI-007 was statistically significantly better than risperidone on key safety and tolerability parameters and exhibited a safety profile similar to placebo. This replicates the safety and tolerability findings of a previous study (our Phase 2 Study 005) in which the efficacy of ITI-007 60 mg and risperidone, the active control, were similar.
Aegerion Pharma (NASDAQ: AEGR) 33% HIGHER; announced that Japans Ministry of Health, Labor & Welfare (MHLW) has approved JUXTAPID for patients with homozygous familial hypercholesterolemia (HoFH).
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) 17% LOWER; announced that it intends to offer shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent (15%) of the number of shares of common stock sold in the offering solely to cover over-allotments, if any. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. H.C. Wainwright & Co. is acting as sole book-running manager for the offering.
Progress Software (NASDAQ: PRGS) 9.3% LOWER; reported Q3 EPS of $0.44, $0.01 worse than the analyst estimate of $0.45. Revenue for the quarter came in at $102 million versus the consensus estimate of $104.72 million. GUIDANCE: Progress Software sees FY2016 EPS of $1.57-$1.60, versus the consensus of $1.61. Progress Software sees FY2016 revenue of $412-415 million, versus the consensus of $414.09 million. Progress Software sees Q4 2016 EPS of $0.55-$0.58, versus the consensus of $0.58. Progress Software sees Q4 2016 revenue of $123-126 million, versus the consensus of $122.65 million.
Pier 1 Imports (NYSE: PIR) 3% HIGHER; reported Q2 EPS of ($0.05), in-line with the analyst estimate of ($0.05). Revenue for the quarter came in at $405.8 million versus the consensus estimate of $406.96 million. Company comparable sales for the quarter decreased 4.3%. GUIDANCE: Pier 1 Imports sees Q3 2017 EPS of $0.09-$0.15, versus the consensus of $0.12. Pier 1 Imports sees Q4 2017 EPS of $0.24-$0.32.
Globalstar, Inc. (NYSE: GSAT) 3% HIGHER; Company and its partner, ADS-B Technologies, announced the completion of the NASA Langley Research Center research flight with the Cirrus SR22 Unmanned Aerial System (UAS) Surrogate designed to test the operation of the ADS-B Link Augmentation System (ALAS). Initial results indicated continuous communication between the aircraft and Globalstars satellite system with only brief interruptions during extreme maneuvering, which reconnected quickly.
Himax Technologies (NASDAQ: HIMX) 1.8% HIGHER; Roth Capital initiated coverage with a Buy rating and a price target of $10.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- After-Hours Stock Movers 01/19: (SWKS) (QRVO) (NVAX) Higher; (AFMD) (SGYP) (IBM) Lower (more...)
- Zynerba Pharma (ZYNE) Prices 2.8M Shares at $18 Per Share
- Stemline Therapeutics (STML) Prices 4.5M Shares at $10